Real-World Analysis Compares Inpatient and Outpatient CAR T-Cell Therapy in MCL and Follicular LymphomaMarch 24th 2023
Inpatient infusion was linked with greater comorbidity burden and increased likelihood of adverse effects in patients with follicular lymphoma who received CAR T-cell therapy, but not in those with mantle cell lymphoma.
Pembrolizumab Plus Chemotherapy Continues to Display Survival Advantage Over Chemotherapy in NSCLCMarch 24th 2023
Patients with metastatic squamous non–small cell lung cancer experienced a clinically meaningful survival benefit when treated with pembrolizumab in combination with chemotherapy.
Nonpharmacologic Pain Intervention Reduces Opioid Use Following Minimally Invasive Gynecologic and Urologic SurgeryMarch 23rd 2023
The implementation of a nonpharmacologic pain intervention bundle helped decrease opioid use among patients recovering from gynecologic and urologic surgeries at a comprehensive cancer center.
Patritumab Deruxtecan Makes Headway in Early Phase Trials for Patients With Metastatic EGFR+ NSCLC and HER3+ Breast CancerMarch 21st 2023
Patritumab deruxtecan generated activity in patients with metastatic or unresectable EGFR-mutated non–small cell lung cancer and HER3-expressing breast cancer.
Mirvetuximab Soravtansine Offers New Path Forward for Patients with Frα-Positive Platinum-Resistant Ovarian CancerMarch 13th 2023
Kathleen Lutz, RN, NP-BC WH, weighs in on the recent approval of mirvetuximab soravtansine-gynx for patients with folate receptor alpha (Frα)-positive, platinum-resistant ovarian cancer.